Modification of osteoarthritis in the guinea pig with pulsed low-intensity ultrasound treatment

Authors

I. Gurkan, A. Ranganathan, X. Yang, W.E. Horton Jr., M. Todman, J. Huckle, N. Pleshko, R.G. Spencer

Abstract

The Hartley guinea pig develops articular cartilage degeneration similar to that seen in idiopathic human osteoarthritis (OA). We investigated whether the application of pulsed low-intensity ultrasound (PLIUS) to the Hartley guinea pig joint would prevent or attenuate the progression of this degenerative process. Treatment of male Hartley guinea pigs was initiated at the onset of degeneration (8 weeks of age) to assess the ability of PLIUS to prevent OA, or at a later age (12 months) to assess the degree to which PLIUS acted to attenuate the progression of established disease. PLIUS (30mW/cm2) was applied to stifle joints for 20min/day over periods ranging from 3 to 10 months, with contralateral limbs serving as controls. Joint cartilage histology was graded according to a modified Mankin scale to evaluate treatment effect. Immunohistochemical staining for interleukin-1 receptor antagonist (IL-1ra), matrix metalloproteinase (MMP)-3, MMP-13, and transforming growth factor (TGF)-β1 was performed on the cartilage to evaluate patterns of expression of these proteins. PLIUS did not fully prevent cartilage degeneration in the prevention groups, but diminished the severity of the disease, with the treated joints showing markedly decreased surface irregularities and a much smaller degree of loss of matrix staining as compared to controls. PLIUS also attenuated disease progression in the groups with established disease, although to a somewhat lesser extent as compared to the prevention groups. Immunohistochemical staining demonstrated a markedly decreased degree of TGF-β1 production in the PLIUS-treated joints. This indicates less active endogenous repair, consistent with the marked reduction in cartilage degradation. PLIUS exhibits the ability to attenuate the progression of cartilage degeneration in an animal model of idiopathic human OA. The effect was greater in the treatment of early, rather than established, degeneration.

Link to Article

http://dx.doi.org/10.1016/j.joca.2010.01.006

Proteinase-activated Receptor-2 Gene Disruption Limits the Effect of Osteoarthritis on Cartilage in Mice: A Novel Target in Joint Degradation

Authors

Nathalie Amiable, Johanne Martel-Pelletier, Bertrand Lussier, Steeve Kwan Tat, Jean-Pierre Pelletier, Christelle Boileau

Abstract

Evidence indicates that proteinase-activated receptor (PAR)-2 participates in the degradative processes of human osteoarthritis (OA). We evaluated the in vivo effect of PAR-2 on articular lesions in a PAR-2-knockout (KO) mouse model of OA. Methods.OA was surgically induced by destabilization of the medial meniscus of the right knee in C57Bl/6 wild-type (WT) and PAR-2 KO mice. Knee swelling was measured throughout the duration of the study (8 weeks postsurgery) and histologic evaluation of cartilage was done to assess structure, cellularity, matrix staining, and remodeling in the deep zone. Morphometric analysis of subchondral bone was also performed. Data showed significant knee swelling in the operated WT mice immediately following surgery, which increased with time (8 weeks post-surgery). Knee swelling was significantly lower (p ≤ 0.0001) in PAR-2 KO mice than in WT mice at both 4 and 8 weeks postsurgery. Cartilage damage was found in both operated WT and PAR-2 KO mice; however, lesions were significantly less severe (global score; p ≤ 0.05) in the PAR-2 KO mice at 4 weeks postsurgery. Operated WT mice showed reduced subchondral bone surface and trabecular thickness with significance reached at 4 weeks (p ≤ 0.03 and p ≤ 0.05, respectively), while PAR-2 KO mice demonstrated a gradual increase in subchondral bone surface with significance reached at 8 weeks (p ≤ 0.007). We demonstrated the in vivo implication of PAR-2 in the development of experimental OA, thus confirming its involvement in OA joint structural changes and reinforcing the therapeutic potential of a PAR-2 antagonist for treatment of OA.

Link to Article

http://dx.doi.org/10.3899/jrheum.100710

c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis

Authors

Ricardo T Paniagua, Anna Chang, Melissa M Mariano, Emily A Stein, Qian Wang, Tamsin M Lindstrom, Orr Sharpe, Claire Roscow, Peggy P Ho, David M Lee, and William H Robinson

Abstract

Tyrosine kinases are key mediators of multiple signaling pathways implicated in rheumatoid arthritis (RA). We previously demonstrated that imatinib mesylate--a Food and Drug Administration (FDA)-approved, antineoplastic drug that potently inhibits the tyrosine kinases Abl, c-Kit, platelet-derived growth factor receptor (PDGFR), and c-Fms--ameliorates murine autoimmune arthritis. However, which of the imatinib-targeted kinases is the principal culprit in disease pathogenesis remains unknown. Here we examine the role of c-Fms in autoimmune arthritis. We tested the therapeutic efficacy of orally administered imatinib or GW2580, a small molecule that specifically inhibits c-Fms, in three mouse models of RA: collagen-induced arthritis (CIA), anti-collagen antibody-induced arthritis (CAIA), and K/BxN serum transfer-induced arthritis (K/BxN). Efficacy was evaluated by visual scoring of arthritis severity, paw thickness measurements, and histological analysis. We assessed the in vivo effects of imatinib and GW2580 on macrophage infiltration of synovial joints in CIA, and their in vitro effects on macrophage and osteoclast differentiation, and on osteoclast-mediated bone resorption. Further, we determined the effects of imatinib and GW2580 on the ability of macrophage colony-stimulating factor (M-CSF; the ligand for c-Fms) to prime bone marrow-derived macrophages to produce tumor necrosis factor (TNF) upon subsequent Fc receptor ligation. Finally, we measured M-CSF levels in synovial fluid from patients with RA, osteoarthritis (OA), or psoriatic arthritis (PsA), and levels of total and phosphorylated c-Fms in synovial tissue from patients with RA. GW2580 was as efficacious as imatinib in reducing arthritis severity in CIA, CAIA, and K/BxN models of RA. Specific inhibition of c-Fms abrogated (i) infiltration of macrophages into synovial joints of arthritic mice; (ii) differentiation of monocytes into macrophages and osteoclasts; (iii) osteoclast-mediated bone resorption; and (iv) priming of macrophages to produce TNF upon Fc receptor stimulation, an important trigger of synovitis in RA. Expression and activation of c-Fms in RA synovium were high, and levels of M-CSF were higher in RA synovial fluid than in OA or PsA synovial fluid. These results suggest that c-Fms plays a central role in the pathogenesis of RA by mediating the differentiation and priming of monocyte lineage cells. Therapeutic targeting of c-Fms could provide benefit in RA.

Link to Article

http://dx.doi.org/10.1186/ar2940

A rate-limiting role for DKK1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody

Authors

Helmut Glantschnig, Kevin Scott, Richard Hampton, Nan Wei, Paul McCracken, Pascale Nantermet, Jing Zhao, Salvatore Vitelli, Lingyi Huang, Peter Haytko, Ping Lu, John Fisher, Punam Sandhu, Jacquellynn Cook, Donald Williams, William Strohl, Osvaldo Flores, Donald Kimmel, Fubao Wang and An Zhiqiang

Abstract

Genetic studies have linked both osteoporotic and high bone mass (HBM) phenotypes to LDL-receptor related proteins (LRP 4/5/6). LRP are receptors for inhibitory Dickkopf-1 (DKK1) protein and treatment modalities that modulate LRP/DKK1 binding may therefore act as stimulators of bone mass accrual. Here we report that RH2-18, a fully human monoclonal anti-DKK1 antibody elicits systemic pharmacologic bone efficacy and new bone formation at endosteal bone surfaces in vivo in a mouse model of estrogen deficiency induced osteopenia. This was paralleled by partial-to-complete resolution of osteopenia (bone mineral density, BMD) at all skeletal sites investigated in femur and lumbar-vertebral bodies and the restoration of trabecular bone micro-architecture. Importantly, testing of RH2-18 in adult, osteopenic rhesus macaques demonstrated a rate limiting role of DKK1 at multiple skeletal sites and responsiveness to treatment. In conclusion, this study provides pharmacologic evidence for modulation of DKK1 bioactivity in the adult osteopenic skeleton as a viable approach to resolve osteopenia in animal models. Thus, data described here suggest that targeting DKK1 through means such as a fully-human anti-DKK1-antibody provides a potential bone-anabolic treatment for postmenopausal osteoporosis.

Link to Article

http://dx.doi.org/10.1124/jpet.111.181404

Analysis of osteoarthritis in a mouse model of the progeroid human DNA repair syndrome trichothiodystrophy

Authors

Sander M. Botter, Michel Zar, Gerjo J. V. M van Osch, Harry van Steeg, Martijn E. T. Dollé, Jan H. J. Hoeijmakers, Harrie Weinans, and Johannes P. T. M. van Leeuwen

Abstract

The increasing average age in developed societies is paralleled by an increase in the prevalence of many age-related diseases such as osteoarthritis (OA), which is characterized by deformation of the joint due to cartilage damage and increased turnover of subchondral bone. Consequently, deficiency in DNA repair, often associated with premature aging, may lead to increased pathology of these two tissues. To examine this possibility, we analyzed the bone and cartilage phenotype of male and female knee joints derived from 52- to 104-week-old WT C57Bl/6 and trichothiodystrophy (TTD) mice, who carry a defect in the nucleotide excision repair pathway and display many features of premature aging. Using micro-CT, we found bone loss in all groups of 104-week-old compared to 52-week-old mice. Cartilage damage was mild to moderate in all mice. Surprisingly, female TTD mice had less cartilage damage, proteoglycan depletion, and osteophytosis compared to WT controls. OA severity in males did not significantly differ between genotypes, although TTD males had less osteophytosis. These results indicate that in premature aging TTD mice age-related changes in cartilage were not more severe compared to WT mice, in striking contrast with bone and many other tissues. This segmental aging character may be explained by a difference in vasculature and thereby oxygen load in cartilage and bone. Alternatively, a difference in impact of an anti-aging response, previously found to be triggered by accumulation of DNA damage, might help explain why female mice were protected from cartilage damage. These findings underline the exceptional segmental nature of progeroid conditions and provide an explanation for pro- and anti-aging features occurring in the same individual.

Link to Article

http://dx.doi.org/10.1007/s11357-010-9175-3

Osteoarthritis induction leads to early and temporal subchondral plate porosity in the tibial plateau of mice: An in vivo micro CT study

Authors

Sander M. Botter, Gerjo J.V.M van Osch, Stefan Clockaerts, Jan H. Waarsing, Harrie Weinans, Johannes P.T.M. van Leeuwen

Abstract

In osteoarthritis (OA) changes occur both in cartilage and subchondral bone. The subchondral bone plate facilitates normal crosstalk between articular cartilage and trabecular subchondral bone, and adaptive changes in the plate due to OA may therefore disturb crosstalk homeostasis. To investigate these changes over time we examined the cartilage-subchondral bone interface using a combined approach of histology and in vivo micro CT. Male C57Bl/6 mice (n=8), aged 16 weeks, received intra-articular injections with collagenase in one joint to induce instability-related OA and saline into the contralateral knee joint (controls). At 2, 4, 6, 10 and 14 weeks post-injection, changes in the tibial subchondral bone plate and subchondral trabeculae were analyzed. At two weeks post-injection, collagenase injected joints had significantly more cartilage damage and osteophytosis than control joints. Osteoclast activity directly underneath the subchondral bone plate was significantly elevated (Oc.S./BS controls: 7.60± 0.81%; OA: 11.07± 0.79%), causing the plate to become thinner and creating a large increase in subchondral bone plate porosity (cumulative porosity volume controls: 0.05e-3 ± 0.04e-3 mm3; OA: 2.52e-3 ± 0.69e-3 mm3). At four weeks post-injection, the previously formed perforations disappeared, coinciding with a significant rise in osteoblast activity in the subchondral trabecular bone (bone formation rate controls: 0.30± 0.03, OA: 0.62± 0.13 μm2/μm3*day). The current study provides for the first time quantitative longitudinal data on the dynamic changes in the subchondral bone plate after OA induction. The development of plate perforations may enhance mutual interaction between subchondral trabeculae, bone marrow cells and the articular cartilage in OA.

Link to Article

http://dx.doi.org/10.1002/art.30307